- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma | 1 | Cision News | ||
| 03.06. | ELICERA THERAPEUTICS AB: Elicera publishes annual report for 2025 | 1 | Cision News | ||
| 01.06. | Elicera Therapeutics AB: Elicera announces outcome of the rights issue | 228 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 25.05. | Elicera Therapeutics AB: Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved | 410 | GlobeNewswire (Europe) | Gothenburg, May 25, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 13.05. | Elicera Therapeutics AB: Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO | 198 | GlobeNewswire (Europe) | Gothenburg, May 13, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 12.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.05.2026 | 1.193 | Xetra Newsboard | Das Instrument MIH0 US6067934041 MITSUBISHI HEAV.IN. ADR/1 EQUITY wird cum Kapitalmassnahme gehandelt am 12.05.2026 und ex Kapitalmassnahme am 13.05.2026 The instrument MIH0 US6067934041 MITSUBISHI... ► Artikel lesen | |
| 11.05. | Elicera Therapeutics AB: Elicera publishes information document regarding the rights issue | 347 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics carries out a rights issue of approximately SEK 73 million | 251 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026 | 174 | GlobeNewswire (Europe) | First quarter (January-March 2026)
Operating profit/loss amounted to SEK -5,116,779 (-8,069,404).
Loss for the period amounted to SEK -5,060,060 (-8,013,462).
Cash flow from operating activities... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics AB: Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu | 273 | GlobeNewswire (Europe) | Gothenburg, March 20, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.03. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate | 190 | GlobeNewswire (Europe) | Gothenburg, March 11, 2023 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 10.03. | Elicera Therapeutics' Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden) | 1 | Cision News | ||
| 06.03. | Elicera Therapeutics AB: Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients | 245 | GlobeNewswire (Europe) | Gothenburg, March 6, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 27.02. | Elicera Therapeutics AB: Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway | 788 | GlobeNewswire (Europe) | Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today... ► Artikel lesen | |
| 18.02. | Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference | 4 | Cision News | ||
| 13.02. | Elicera Therapeutics AB Q4 Loss Widens | 1 | RTTNews | ||
| 13.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-End 1 January - 31 December 2025 | 202 | GlobeNewswire (Europe) | Fourth quarter (October-December 2025)
Operating loss amounted to o SEK -7,129,626 (-2,911,958).
Loss for the period amounted to SEK -6,965,286 (-2,603,242).
Cash flow from operating activities... ► Artikel lesen | |
| 11.02. | Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study | 1 | Cision News | ||
| 22.01. | Elicera Therapeutics' CSO invited to present at multiple scientific conferences | 1 | Cision News | ||
| 09.01. | Elicera Therapeutics AB: Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors | 290 | GlobeNewswire (Europe) | Gothenburg, January 9, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,942 | -0,96 % | Enteignungsangst, Skalierung und neue Phantasien - Evotec, dynaCERT, Vonovia | Drei Unternehmen aus verschiedenen Sektoren stehen an entscheidenden Wendepunkten. Der erste Wert ist ein führender Immobilienkonzern, der nun massiv vom Wegfall politischer Enteignungsrisiken profitiert... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 577,50 | -0,77 % | Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2 | ||
| BRAIN BIOTECH | 2,810 | +1,08 % | EQS-Adhoc: BRAIN Biotech AG: BRAIN Biotech vereinbart neue revolvierende Kreditlinie mit der MP Beteiligungs-GmbH | EQS-Ad-hoc: BRAIN Biotech AG / Schlagwort(e): Kapitalmaßnahmen / bedeutender Kreditvertrag
BRAIN Biotech AG vereinbart neue revolvierende Kreditlinie mit der MP Beteiligungs-GmbH... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| CARDIOL THERAPEUTICS | 0,906 | +2,84 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| CSL | 74,77 | -0,35 % | CSL shares are up 35% since early June. Is the recovery here to stay? | ||
| BURCON NUTRASCIENCE | 1,140 | -1,72 % | Stonegate, Inc.: Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) 4Q26 | Dallas, Texas--(Newsfile Corp. - June 26, 2026) - Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). Burcon... ► Artikel lesen | |
| MANNKIND | 3,535 | -1,42 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,600 | -3,91 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,354 | -4,58 % | Oxford Nanopore shares plummet as warns of first half revenue miss | ||
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 2,008 | -3,92 % | Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform | REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| CORMEDIX | 7,266 | -1,20 % | CorMedix, Inc.: U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin Patent Litigation | PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of... ► Artikel lesen | |
| TELO GENOMICS | 0,026 | -1,89 % | Telo Genomics Corp.: Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma | Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 5,500 | -4,68 % | Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection | SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,007 (-2,87 %) liegt der Kurs bei 0,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.